Allergan (AGN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Remains Sidelined on Allergan (AGN) Following Mixed 2Q
August 9, 2016 9:08 AM EDTPiper Jaffray maintained a Neutral rating on Allergen (NYSE: AGN), and cut the price target to $227.00 (from $236.00), following the company's 2Q earnings report. AGN reported non-GAAP diluted EPS of $3.35 on revenue of $3.68B, compared to Street estimates of $3.33 and $3.97B, respectively.
Analyst David Amsellem commented, "Allergan... More
Allergan (AGN) CEO Says Not Focused on or Looking at Large Deals (BIIB)
August 8, 2016 9:21 AM EDTAllergan's (NYSE: AGN) CEO said the company isn't focused on or looking at large deals.
Traders are watching shares of rumored target Biogen (NASDAQ: BIIB) following the comments.
... MoreAllergan (AGN) August weekly volatility flat into Q2 and outlook
August 8, 2016 6:18 AM EDTAllergan (NYSE: AGN) August weekly call option implied volatility is at 35, August and September is at 28; compared to its 52-week range of 20 to 53 into the expected release of Q2 results today.
... More